Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We are currently developing three product candidates under our INOpulse pro... more >

more >

Recent News

12/17/19

Summary Toggle Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity Bellerophon Intends to Initiate Pivotal Phase 3 in First Quarter of 2020 Company Enters Into $10M Convertible Financing Facility Led By Existing Institutional Shareholders, Extending Cash Runway to 2021
11/12/19

Summary Toggle Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

WARREN, N.J. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive initial data from an acute, dose escalation, clinical study (PHPF-002) of INOpulse® for the treatment
11/07/19

Summary Toggle Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019

Data Include New Results from Subgroup Analysis of Cohort 1 Further Demonstrating Benefits of INOpulse WARREN, N.J. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, is presenting data from

more >

Stock Quote

more >

Bellerophon (: )

Data as of 01/27/20 2:58 PM EST

more >

Presentations

Corporate Presentation

01/21/20

Corporate Presentation 1.4 MB
PFF 2019 Poster - Sub-Group Analysis

11/08/19

PFF 2019 Poster - Sub-Group Analysis 217.3 KB
PFF 2019 Poster - Actigrpahy Endpoint

11/08/19

PFF 2019 Poster - Actigrpahy Endpoint 252.4 KB
American College of Chest Physicians Conference Presentation

10/23/19

American College of Chest Physicians Conference Presentation 537.5 KB
KOL Day Presentation

05/30/19

KOL Day Presentation 4 MB
2019 ATS PH-ILD Presentation

05/21/19

2019 ATS PH-ILD Presentation 452.8 KB
ATS 2019 PH-ILD Poster

05/21/19

ATS 2019 PH-ILD Poster 310.5 KB
2019 PVRI Poster – iNO DDI Study

02/02/19

2019 PVRI Poster – iNO DDI Study 339.9 KB
2019 PVRI Poster – Actigraphy in PH-PF

02/02/19

2019 PVRI Poster – Actigraphy in PH-PF 562 KB
Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan

08/09/17

Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan 4.5 MB
2017 ATS Poster - PH-IPF

05/23/17

2017 ATS Poster - PH-IPF 2.2 MB
2017 ATS Poster - PH-COPD

05/23/17

2017 ATS Poster - PH-COPD 3 MB
2017 ISHLT Poster

04/06/17

2017 ISHLT Poster 417.9 KB
2016 ATS Poster

05/19/16

2016 ATS Poster 971 KB
2015 PHPN Poster

09/19/15

2015 PHPN Poster 684.5 KB

Investors

Corporate Profile

Recent News

Stock Quote

Upcoming Events

Presentations

Corporate Presentation

PFF 2019 Poster - Sub-Group Analysis

PFF 2019 Poster - Actigrpahy Endpoint

American College of Chest Physicians Conference Presentation

KOL Day Presentation

2019 ATS PH-ILD Presentation

ATS 2019 PH-ILD Poster

2019 PVRI Poster – iNO DDI Study

2019 PVRI Poster – Actigraphy in PH-PF

Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan

2017 ATS Poster - PH-IPF

2017 ATS Poster - PH-COPD

2017 ISHLT Poster

2016 ATS Poster

2015 PHPN Poster